Immuno-oncology products have demonstrated comparable respective efficacy and safety profiles.
Johnson & Johnson shares have risen 11 percent in the last 12 months.
The study is particularly significant because it demonstrates the strength of cancer immunotherapy at advanced stages, in stopping the disease from returning. It is also the first study to look at long-term survival for an anti-PD-1 agent.
These results bode well for individuals suffering from this disease.
The latest epidemic has linked the virus to fetal brain-development disorders and Guillain-Barre syndrome.
The goal is to evaluate the efficacy and safety profile of the drug in patients with inflammatory hand osteoarthritis.
An experimental epilepsy drug made from cannabis plants grown in England is complicating the medical marijuana debate in hospitals and statehouses.
Stem-like breast cancer cells secrete molecules that allow neighboring, otherwise anchored cells to metastasize.
Another senior Republican said additional Zika money most likely wouldn't come before September at the earliest.
Diagnosis of dementia in older HIV-infected individuals is on the rise.
Pancreatic cancer is the third leading cause of cancer deaths in the United States.
Chances are, you or someone you know is a coffee drinker.
A recent study investigated whether a higher dose of liraglutide may lead to greater weight loss.
The current study was prepared to provide data supporting the response to the proposed changes from several allergy and immunology specialty organizations.
Welcome to Drug Discovery Spotlight — we’ve rounded up this week’s top news, trending headlines, and all-around interesting reads.